top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Advance in the Treatment of Pediatric Leukemia
Advance in the Treatment of Pediatric Leukemia
Autore Handgretinger Rupert
Pubbl/distr/stampa Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica 1 electronic resource (300 p.)
Soggetto topico Research & information: general
Chemistry
Soggetto non controllato acute lymphoblastic leukemia
pediatric
advances
diagnosis
treatment
immunotherapy
bispecific T-cell engager (BiTE)
BCP-ALL
leukemia
TRAIL
antibody
Fc-engineering
xenograft
CD19
juvenile myelomonocytic leukemia
RAS signaling
hematopoietic stem cell transplantation
5-azacitidine
myelodysplastic/myeloproliferative disorders
targeted therapy
ADC
antibody-drug conjugate
pediatric leukemia
ALL
AML
allogeneic stem cell transplantation
acute myeloid leukemia
minimal residual disease
conditioning regimen
alternative donors
B-ALL
DUX4
IKZF1
PAX5
Ph-like
ZNF384
NUTM1
T-ALL
NOTCH1
BCL11B
transcriptome
genome
chronic myeloid leukemia
CML
tyrosine kinase inhibitor
immunizations
COVID-19
childhood acute lymphoblastic leukemia
low-risk ALL
risk-stratified treatment
treatment related toxicity
L-asparaginase
acute pancreatitis
polymorphism
SNV
ABCC4
CFTR
other extramedullary relapse
lymphoblastic leukemia
children
prognosis
evolution of CAR T cells
FDA-approved CAR products
TcR versus CAR
limitations and complications of CAR T cell therapy
future directions of CAR T cell therapy
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910576878903321
Handgretinger Rupert  
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Immunotherapy, Tumor Microenvironment and Survival Signaling
Immunotherapy, Tumor Microenvironment and Survival Signaling
Autore Golubovskaya Vita
Pubbl/distr/stampa Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica 1 electronic resource (376 p.)
Soggetto topico Medicine
Clinical & internal medicine
Soggetto non controllato Autophagy
colorectal cancer
immunotherapy
tumor stroma
tumor microenvironment
immune checkpoint inhibitors
chemotherapy
tyrosine kinase inhibitors
angiogenesis
check point inhibitors
programmed cell death protein 1
programmed cell death 1 ligand 1
cardiotoxicity
lung metastasis
CAR-T
hypoxia
tumor
microenvironment
CD19
BCMA
cancer
melanoma
immune escape
antigen loss
chimeric antigen receptor
electroporation
lentivirus
lentiviral transduction
macrophages
leukemia cells
lytic peptides
targeted therapy
dendritic cells
pathogenesis
risk factors
breast cancer
resistance
checkpoint
targeted treatment
personalized medicine
pediatric solid tumors
chimeric antigen receptors
cancer vaccines
oncolytic viral therapy
immunomodulation
DCLK1
tumor stem cells
clonogenicity
mitochondria
mitochondrial transfer
tunneling nanotubes
triple-negative breast cancer
immune checkpoint inhibitor
combination therapy
cancer nanomedicine
tumor antigens
cancer metabolism
cancer immunotherapy
nanoparticles
immunotherapeutic agent
immunomodulators
tuft cells
cancer stem cells
immunotherapies
myeloid-derived suppressor cells
regulatory T cells
crosstalk
tumor immune evasion
cell-cell contact
β2 integrins
CD18
CD11
CAR-T cells
CD37
cell therapy
tumor antigen
lymphoma
CAR macrophage
CAR T cell
solid tumors
immunometabolism
miRNA
immunogenic cell death
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910580205403321
Golubovskaya Vita  
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui